Oncolytics Biotech IncOncolytics Biotech Inc
Oncolytics Biotech Inc

Oncolytics Biotech Inc

ONCY
Health Care·Biotechnology

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Alberta; Canada
Market cap
No dataNo data
Revenue
-388KNo data
Net income
-28.8MNo data
Free cash flow
-20.1MNo data

Market

Listed stock
ONCYPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
-388KNo data
Operating income
-28.7MNo data
Net income
-28.8MNo data
Free cash flow
-20.1MNo data

Revenue, profit & cash trend

Revenue
Reference
Revenue: 2021 0, 2025 -388K. Reference line: Reference at 0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 -20.8M, 2022-12-31 -19.8M, 2023-12-31 -25.5M, 2024-12-31 -24.3M, 2025-12-31 -28.7M. Net income: 2021-12-31 -20.8M, 2022-12-31 -18.3M, 2023-12-31 -20.9M, 2024-12-31 -22M, 2025-12-31 -28.8M. Free cash flow: 2021-12-31 -18M, 2022-12-31 -17.3M, 2023-12-31 -21.5M, 2024-12-31 -18.9M, 2025-12-31 -20.1M

Growth heatmap

2025CAGR
Revenue
No data
No data
Gross profitNo data
No data
Operating income
+4.4%
-28.5%
+4.7%
-18.2%
No data
Free cash flow
+4.0%
-24.5%
+12.0%
-6.4%
No data

Earnings quality

Operating cash flow
-20.1MNo data
Net income
-28.8MNo data
Free cash flow
-20.1MNo data
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 70%, 2024-12-31 85%, 2023-12-31 103%, 2022-12-31 94%, 2021-12-31 85%. Free cash flow: 2025-12-31 70%, 2024-12-31 86%, 2023-12-31 103%, 2022-12-31 94%, 2021-12-31 86%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data